Close Menu

NEW YORK – Talis Biomedical reported in its Form 10-K that its full-year 2020 revenues more than doubled year over year.

In the document filed on Tuesday with the US Securities and Exchange Commission, the Menlo Park, California-based company said that 2020 revenues grew to $10.9 million from $4.0 million in 2019. 

Talis posted a net loss of $91.1 million, or $42.98 per share, in 2020 compared to a net loss of $27.5 million, or $12.77 per share, in 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.